Background {#Sec1}
==========

Heterogeneity was initially defined for "tumor heterogeneity" by Heppner 35 years ago \[[@CR1]\], referring the observation that different tumor cells can show distinct morphological and phenotypic profiles \[[@CR2]\]. The tumor heterogeneity was observed occurring at two different levels: inter-tumor heterogeneity and intra-tumor heterogeneity. It is believed that the intra-tumor heterogeneity could introduce significant challenges in human treatment strategies \[[@CR3], [@CR4]\]. Actually, heterogeneity is a widely spread phenomenon in all life systems, from genetic diversity to cell-to-cell variation in all cellular processes. In particular, cell to cell heterogeneity (or sometimes called variation) in gene expression has been described and investigated from bacteria to humans, which may be a key link between upstream genetic diversity and downstream phenotypic heterogeneity. Recent studies have indicated that cells even from an apparently homogeneous population show variation in expression and in response to environmental stimulations \[[@CR5]--[@CR7]\]. Transcription, a major step of gene expression control, is regulated by multiple factors in eukaryotic systems, including sequences of promoters and enhancers, nucleosome occupancy and position, epigenetic modification and long-range chromatin interaction \[[@CR8]--[@CR20]\]. Thus, the variation in gene expression in eukaryotic cells may result from numerous mechanisms including fluctuations of upstream regulators, such as promoter, enhancer, and insulator, temporal variations of epigenetic modification states or long-range interactions \[[@CR14]\] or stochastic bursts of transcription \[[@CR21]\]. Recent studies with new single-cell epigenomics techniques have revealed new insights into the underlying mechanism of cellular heterogeneity \[[@CR16], [@CR22]--[@CR24]\]. In particular, enhancer--promoter interactions mediated by CCCTC-Binding Factor (CTCF) plays a critical role in the control of cell-to-cell variation in gene expression \[[@CR14]\].

CTCF acts as chromatin barrier and enhancer blocker {#Sec2}
---------------------------------------------------

CTCF gene encodes a transcriptional regulator protein with 11 highly conserved zinc finger (ZF) domains which exhibit almost identical amino acid sequences among vertebrates, and more divergent in N and C terminals \[[@CR25]\]. It is required for normal embryonic development and cellular differentiation \[[@CR26]--[@CR28]\]. The using of different combination of eleven ZF domains allows this protein to bind different DNA sequence and/or interact with various protein factors. Depending on the context, it can function as a transcriptional activator or repressor \[[@CR25]\]. In early studies, CTCF was considered as a transcriptional repressor using reporter gene assays for the regulatory regions of chicken and human *c*-*Myc* genes \[[@CR29], [@CR30]\]. Soon after, it was found that it could act as a transcriptional activator at the Amyloid β-Protein Precursor TSS \[[@CR31]\]. Later on, CTCF was found to have the enhancer blocking and/or barrier insulation activity at the chicken β-globin locus and at the imprinted control region (ICR) of the mammalian *H19/Igf2* locus \[[@CR32]--[@CR34]\]. This ability was defined by the capacity to block the communication between promoter and regulatory elements such as enhancers, and also the spread of repressive heterochromatin from adjacent genetic regions \[[@CR35]\]. Consistent with this function, CTCF binding enriched at the boundary regions demarcates active and repressive chromatin domains marked by H2AK5Ac and H3K27me3 in human cells \[[@CR36]\].

CTCF contributes to higher-order genome organization {#Sec3}
----------------------------------------------------

The mammalian genomes are organized into megabase-sized local chromatin interaction domains, the topologically associating domains (TADs) defined from Hi-C interactions \[[@CR9]\]. TADs tend to tally with epigenetic domains, contain co-regulated genes, and are highly conserved across cell types and species \[[@CR9], [@CR15], [@CR37], [@CR38]\]. TADs can be divided into smaller domains with enhanced contact frequency, named DNA loops or sub-TADs, which are more variable across different cell types \[[@CR11], [@CR15], [@CR39]\]. TAD boundaries are often associated with CTCF binding to its motifs of convergent orientation \[[@CR11]\]. Disruption of the CTCF binding sites at TAD boundaries causes the loss of TAD structure and dysregulation of transcription of genes within the TADs \[[@CR40]--[@CR43]\], suggesting a critical role of CTCF protein in maintaining the TADs structure in genome. CTCF and Cohesin-mediated loop formation results in insulated chromatin domains, which is critical for the proper expression or repression of local genes involved in pluripotency or lineage specification in mouse ES cells \[[@CR44]\]. Deletion of the CTCF target sites leads to inappropriate interaction of enhancers inside the neighborhood with genes outside the neighborhood and thus improper expression of relevant genes \[[@CR44]\]. Similarly, the CTCF binding sites within the *Hox* gene clusters function to insulate adjacent chromatin domains during embryonic stem cell differentiation into cervical motor neurons. Deletion of CTCF binding sites results in the expansion of active chromatin into the repressive domain, causing *Hox* genes' dysregulation \[[@CR45]\]. A loop exclusion model was proposed to explain the requirement of two convergent CTCF motifs for loop formation \[[@CR46]--[@CR48]\]. In this model, two convergently bound CTCFs act as extrusion barriers, Cohesin complex serves as extruding factors. When Cohesin is halted in both directions by bound CTCFs, the loop is formed \[[@CR46], [@CR47]\]. Supporting this model, it was found that single nucleotide mutation of CTCF motif sequence or inversion of core motif DNA sequence of CTCF resulted in disruption of the TADs structure and dysregulation of nearby genes \[[@CR49], [@CR50]\]. The deletion or inversion of DNA sequence that disrupts a CTCF-associated boundary domain causes limb enhancer misplaced relative to TAD boundaries and drives ectopic limb expression in human limb malformations \[[@CR20]\].

The contribution of CTCF to TADs structure was also shown by different strategies to control CTCF expression. Knocking down of CTCF expression using siRNAs not only reduced the intradomain interactions but also increased interactions between neighboring domains \[[@CR51]\]. More recently, by acute and reversible depletion of CTCF using the auxin-inducible degron (AID) system in mESCs, Nora and colleagues elegantly demonstrated that CTCF is indispensable and dose-dependently required for looping between CTCF target sites and insulation of TADs. Depletion of CTCF eliminates CTCF-mediated DNA looping and TADs genome-wide \[[@CR42]\].

CTCF facilitates enhancer--promoter interaction {#Sec4}
-----------------------------------------------

Although CTCF binding is enriched in TAD boundaries and important for TAD structure, CTCF binding sites are widespread in the genome and actually the vast majority of them are located within TADs \[[@CR10], [@CR12], [@CR14], [@CR35], [@CR51]--[@CR53]\] structure. Furthermore, these intra-domain CTCF binding sites are in the vicinity of potential enhancers of transcription, marked by P300 and H3K4me1, and thus may influence the activity of enhancers \[[@CR14]\]. A chromosome conformation capture carbon copy (5C) study in human GM12878, K562 and HeLa-S3 cells found that a fraction of CTCF enriched distal elements significantly interact with gene promoters, which suggests that one of the main roles of CTCF in genome function may be to facilitate the interaction between regulatory sequences and promoters \[[@CR54]\]. Since distal enhancers must physically contact with their target promoters to carry out their activity, the nearby CTCF molecules may bring enhancers to the vicinity of their target promoters \[[@CR14]\]. CTCF can mediate the enhancer--promoter contact through the interaction between CTCF bound nearby enhancers and Cohesin loaded nearby promoters \[[@CR46], [@CR55], [@CR56]\]. Liu et al. reported that regulatory elements-bound CTCF/cohesin can recruit the core promoter factor TAF3 and mediate its contact with promoters through TAF3-dependent loop formation in ES cells and depletion of CTCF reduces the efficient recruitment of TAF3 to distal regulatory elements, compromises endoderm differentiation marker gene expression, such as Gata4, Afp, and Apoa1 \[[@CR57]\]. CTCF interacts with the enzyme poly-ADP-ribose (PARP1) itself to help establish inter-chromosomal contacts between active circadian loci and repressive chromatin at the lamina, thereby mediates circadian transcriptional plasticity. Furthermore, knockdown of CTCF expression counteracts both recruitment to the repressive lamina at envelope and circadian transcription \[[@CR58]\]. Recently, we systematically profiled CTCF-mediated promoter-enhancer interaction in mouse primary Th2 cells by integrating CTCF ChIP-Seq and 3e Hi-C interaction data. We observed a positive correlation between CTCF binding and enhancer activities as indicated by H3K27ac, suggesting that CTCF binding influences enhancer activity. Furthermore, we found that active promoters exhibit significantly higher interaction with CTCF sites than silent promoters, and the enhancers that interacted with CTCF sites also exhibited significantly higher interaction with promoters, which confirmed that CTCF binding sites interact with their neighboring enhancers and facilitate the functional interaction between enhancers and promoters. Using shRNA knockdown of CTCF, we confirmed that CTCF contributes to the expression of lineage-specific genes by mediating the interaction between their enhancers and promoters. We further found that CRISPR/CAS9-mediated deletion of intra-domain CTCF binding sites significantly compromised the interactions between CTCF binding sites, promoters, and enhancers at *Thy1, Cd5* and *Runx3* gene loci, which, however, did not disrupt the TAD structure. Together, these results indicate that one major role of intra-domain CTCF binding is to mediate the interaction between enhancers and their target promoters \[[@CR14]\].

CTCF contributes to the control of cellular heterogeneity in gene expression {#Sec5}
----------------------------------------------------------------------------

Although there is increasingly convincing evidence showing that CTCF critically contributes to the interaction between enhancers and promoters, depletion of CTCF protein in cells by either shRNA or AID leads to only modest expression changes of relatively small number genes at cell population level. Since the RNA-Seq and Western blotting assays measure the average gene expression level of a population of cells, the observed modest changes in gene expression may reflect one of two ways of gene expression change: (1) modest but similar changes in every cell and (2) little change in the majority of cells but substantial change in a fraction of cells. While the former is consistent with the homogeneous property of all cells, the latter informs the heterogenous property of a cell population. Using quantitative single-cell assays including fluorescence-activated cell sorting (FACS) and single-cell RNA-FISH, we monitored gene expression in each single cell and found that CTCF-bound T cell-specific genes GATA3, CD90, CD28, CD5 displayed significantly increased expression variation in CTCF depleted cells \[[@CR14]\]. These results supported the cellular heterogeneous property of the cells and suggested an important role of CTCF in the control of gene expression heterogeneity. However, the increased cell-to-cell variation of expression by knocking down of CTCF could also be accounted for by the heterogeneous CTCF knockdown efficiency across different cells. Conclusive evidence came from the deletion of a specific CTCF binding site at *Thy1* locus, nearby a distal enhancer, using CRISPR/CAS9, which resulted in a significantly higher cell-to-cell variation of gene expression in the CRISPR knockout cells \[[@CR14]\].

CTCF contributes to cellular heterogeneity control by stabilizing enhancer--promoter interactions {#Sec6}
-------------------------------------------------------------------------------------------------

Recent studies have demonstrated that sequences of promoters, nucleosome occupancy, epigenetic modifications and three dimensional genome organization all contribute to the regulation of gene expression in eukaryotic systems \[[@CR8]--[@CR18]\]. Consequently, gene expression variation may result from any fluctuation of above-mentioned factors, especially for CTCF mediated promoter-enhancer interaction. Recent studies indicated that intra-domain CTCF binding sites are frequently found in enhancer regions \[[@CR12], [@CR14], [@CR51]\]. CTCF binds and brings distal enhancers, via interaction with Cohesin, to the vicinity of their target promoters \[[@CR14]\]. The increased heterogeneity in gene expression by deletion of CTCF binding site at *Thy1* locus is correlated with decreased Thy1 promoter-enhancer interaction but not changes in the TAD structure, strongly suggest a model that CTCF binding near the enhancer region stabilizes the interaction between the *Thy1* promoter and its enhancers and thus reduces the cell-to-cell variation of *Thy1* expression. More studies to visualize the enhancer--promoter interaction in single-cells would be needed in future to prove this model. Next, we discuss other potential mechanisms that CTCF use to contribute to cellular heterogeneity.

The methylation status of CTCF binding motif could affect cellular heterogeneity {#Sec7}
--------------------------------------------------------------------------------

DNA methylation can block CTCF binding in genome \[[@CR34], [@CR59]--[@CR61]\]. The H19 imprinted control region (ICR) is an enhancer-blocking element required for imprinting of the *H19* and *Igf2* genes \[[@CR62]\]. The conserved CTCF sites in HS1 and HS2 of the ICR are essential for the enhancer-blocking activity. The methylation of CTCF binding motifs of these sites abolishes CTCF binding and results in the loss of the epigenetic regulation of *Igf2* \[[@CR59]\]. These observations are consistent with the constitutively methylated status on both alleles in Wilms tumors with loss of *Igf2* imprinting in humans \[[@CR63]\]. Recently, Comparison of genome-wide occupancy patterns of CTCF with bisulfite sequencing data in 19 diverse human cell types, including normal primary cells and immortal lines reveal that 41% of variable CTCF binding is linked to differential DNA methylation, which is enriched at CTCF recognition sequence. Disruption of CTCF binding in immortal cell lines is associated with increased methylation at promoter sites \[[@CR60]\]. Furthermore, the binding of CTCF is sufficient to effect a local demethylation state \[[@CR64]\]. These data suggest that CTCF could contribute to expression variation via regulating dynamics of DNA methylation at regulatory regions. However, CTCF is not the originator of the unmethylated state at *Igf2/H19* gene locus \[[@CR65]\], and also it is unclear whether demethylation facilitates subsequent CTCF binding or whether bound CTCF maintains an unmethylated domain. To test this, Liu and collages employed dCas9-Dnmt3a to target de novo methylation of CTCF motifs in mES cells. Targeting of dCas9-Dnmt3a to the CTCF binding site bordering the *miR290*, *Pou5f1* gene loops blocked CTCF anchoring, resulted in significantly increased interaction frequency between super-enhancers and newly activated genes (*Nlrp12, H2Q10*) in the neighboring loop, and accompanied by increased expression of Nlrp12, H2Q10 \[[@CR61]\]. In humans, IDH mutations, which mis-regulates genome methylation and compromise CTCF binding, promote gliomagenesis by disrupting chromosomal topology and allowing aberrant regulatory interactions that induce oncogene PDGFRA expression \[[@CR66]\]. These data demonstrate that the de novo change of the methylation state of specific CTCF anchor sites could interfere its insulator/looping function, which may result in increased noise of transcription.

The mutation of CTCF binding motifs may increase expression heterogeneity {#Sec8}
-------------------------------------------------------------------------

The mammalian cells have about 50,000 CTCF binding sites, with 10 to 20% located in TAD boundaries and 60 to 70% located in intra-domain regions \[[@CR11], [@CR12], [@CR36], [@CR44], [@CR52], [@CR67]\]. GWAS studies have identified numerous mutations in CTCF binding sites \[[@CR68], [@CR69]\] and these mutations could affect gene regulation by TAD organization or enhancer--promoter interactions mediated by CTCF and thus increase the variability of gene expression. However, this notion needs more supporting evidence from single cell studies.

CTCF may contribute to cellular heterogeneity by effects on nucleosome positioning {#Sec9}
----------------------------------------------------------------------------------

Nucleosome positioning is an important chromatin feature that regulates gene expression \[[@CR70]--[@CR72]\]. The accessibility of critical regulatory regions in chromatin to transcription factors can be heavily hindered by the nucleosome structure and thus remodeling or removal of the nucleosome structure is required for gene activation \[[@CR73], [@CR74]\]. Recently, we analyzed genome-wide nucleosome positioning in hundreds of single mammalian cells and found that the cell-to-cell variation in nucleosome position is positively correlated with that in DNase hypersensitivity and transcription of underlying genes \[[@CR16]\]. This study suggests that any factor that influences nucleosome positioning may contribute to the cellular heterogeneity in gene expression. Analysis of data from this study indicated that mutations of the CTCF motifs in the genome could result in decreased CTCF binding and nucleosome repositioning \[[@CR16]\], which is consistent with the previous observation that CTCF could induces stable positioned arrays of nucleosome around its binding sites, and also significantly affects local chromatin accessibility during ES differentiation \[[@CR75], [@CR76]\]. Therefore, further investigation is needed to uncover the function of CTCF binding in nucleosome position variation in genome, which clearly, could also leads to expression heterogeneity.

CTCF may contribute to cellular heterogeneity by regulating transcriptional pausing and alternative mRNA splicing {#Sec10}
-----------------------------------------------------------------------------------------------------------------

Alternative mRNA splicing is another source of cellular heterogeneity in mammalian cells. It is estimated that about 90% of human genes undergo alternative splicing of pre-mRNA \[[@CR77]\]. The rate of RNA polymerase II transcription elongation influences splice site selection by the spliceosome, regardless the availability of splicing factors that detect cis regulatory elements \[[@CR78]\]. It was reported that methylation of DNA sequence in the middle of a gene causes a decrease in Polymerase II elongation \[[@CR79]\]. Further studies indicated that increased DNA methylation in exons is associated with increased splicing retention of alternative exons via MeCP2 pathways \[[@CR80]\]. Other studies found that polymerase II tends to stall at CTCF/Cohesin binding sites in living human cells \[[@CR81]\], which may increase the efficiency of pre-RNA splicing. Later on, it was found that the genome-wide CTCF binding at promoter-proximal regions well correlated with high polymerase II pausing indexes, and therefore, the effect of CTCF on RNA Pol II elongation may be widespread \[[@CR82]\]. For example, In the mouse *Myb* locus, CTCF interferes with RNAPII elongation at its first intron, leading to low expression of the Myb \[[@CR83]\]. Since CTCF binding affected by DNA methylation, the methylation status of CTCF binding motifs could regulate pre-RNA splicing. Indeed, Shukla et al. found that CTCF binds to exon 5 of *CD45* gene, pauses polymerase II elongation, results in the inclusion of exon 5 in mRNA; and DNA methylation inhibits CTCF binding to the target site near exon 5, consequently causes the exclusion of exon 5 in mature transcripts \[[@CR84]\]. Therefore, it is highly likely that CTCF may also contribute to cellular heterogeneity by regulating transcriptional pausing and alternative mRNA splicing in mammalian cells.

Cell cycle related dynamics of CTCF and CTCF DNA binding may contribute to cellular heterogeneity {#Sec11}
-------------------------------------------------------------------------------------------------

Progression of cell cycle is associated with specific expression of a group of genes at distinct phases of the cell cycle. For example, *Cdh1* is expressed in G1 phase; histone genes are expressed in S phase; expression of the majority of genes is shut off in M phase. Thus, different phases of cell cycle create a kind of cellular heterogeneity within a population of cells. While it is not clear what is the role of CTCF in controlling the expression of the cell cycle specific genes, CTCF may be involved in the formation of globally distinct chromatin structure during cell cycle progression. It is well established that there are dramatical changes of chromosome organization in mitotic phase \[[@CR85]--[@CR87]\]. Interestingly, TADs and A/B compartments are lost during prometaphase \[[@CR37], [@CR88]\]. However, whether the loss of the high order genome structure is due to the loss of CTCF binding at the prometaphase stage is unknown. Recent data indicated that cell cycle dependent dynamics of CTCF DNA binding results in dynamics of factor binding and nucleosome positioning \[[@CR89], [@CR90]\]. Based on live cell imaging and genomics techniques, it was found that the dynamic changes of chromatin organization between interphase and mitotic phase, especially prometaphase, can be explained by loss and gain of genome wide CTCF binding, accompanied by the rearrangement of the nucleosomes flanking CTCF motifs \[[@CR89]\]. The molecular mechanisms underlying this phenomenon may be related with the cell cycle associated CTCF protein level and phosphorylation status in cells \[[@CR91]--[@CR94]\]. Phosphorylation of CTCF greatly reduces its DNA binding capability, which could explain the observation that CTCF dissociates from chromatin during mitosis \[[@CR92], [@CR93], [@CR95]\]. Taken together, these data suggest that cell cycle related CTCF abundance and its DNA binding dynamics may contribute to cellular heterogeneity during cell cycle progression.

Perspectives {#Sec12}
------------

The emerging theme from recent studies is that cellular heterogeneity could be the output of nucleotide mutation, abnormal of histone modification, transcription factor binding, and also higher order chromosomal structures \[[@CR2], [@CR13], [@CR41], [@CR53], [@CR83], [@CR96]\]. CTCF is a well-studied chromatin protein, which may contribute to transcription regulation by a variety of different mechanisms including facilitating enhancer--promoter interaction, maintaining TAD structure, and influencing transcriptional elongation and splicing of pre-RNAs. Thus, any factor that modulates the CTCF activity in these processes may contribute to cellular heterogeneity. These include post-translational modification of CTCF, point-mutations of CTCF protein itself, CTCF-interacting proteins, mutation and methylation status of CTCF target motifs. In future, new/improved tools, particularly used for single-cell analysis of genome organization, regulatory factors binding, transcription state, and also epigenome information, are required to investigate the contribution of CTCF to cellular heterogeneity and its relevance to normal development and human diseases.
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